American Association for Cancer Research

sorry, we can't preview this file

crc-21-0133-s14.xlsx (315.69 kB)

Supplementary Table 4 from Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade

Download (315.69 kB)
posted on 2023-04-04, 01:43 authored by Gabriel Abril-Rodriguez, Davis Y. Torrejon, Daniel Karin, Katie M. Campbell, Egmidio Medina, Justin D. Saco, Mildred Galvez, Ameya S. Champhekar, Ivan Perez-Garcilazo, Ignacio Baselga-Carretero, Jas Singh, Begoña Comin-Anduix, Cristina Puig-Saus, Antoni Ribas

Supplemental Table 4: Differential gene expression analysis between B16 PAK4 KO anti-PD-1 vs PAK4 KO isotype tumors in vivo at day 10. Showing genes with q < 0.05 and log2FC > 2 or < -2.


HHS | NIH | National Cancer Institute (NCI)

American Society of Clinical Oncology (ASCO)

V Foundation for Cancer Research (VFCR)

Ressler Family Foundation (The Ressler Family Foundation)

Parker Institute for Cancer Immunotherapy (Parker Institute)



Our findings provide new insights into PAK4 inhibition mechanism of action as well as the scientific foundation for specifically blocking PAK4 kinase activity using a novel and specific PAK4 kinase inhibitor to overcome resistance to PD-1 blockade.